Reuters logo
BRIEF-Enanta Pharmaceuticals Q1 loss per share $0.26
February 8, 2017 / 9:10 PM / 9 months ago

BRIEF-Enanta Pharmaceuticals Q1 loss per share $0.26

Feb 8 (Reuters) - Enanta Pharmaceuticals Inc :

* Enanta Pharmaceuticals reports financial results for its fiscal first quarter ended december 31, 2016

* Q1 loss per share $0.26

* Q1 revenue $10.4 million versus I/B/E/S view $11.9 million

* Q1 earnings per share view $-0.18 -- Thomson Reuters I/B/E/S

* Enanta Pharmaceuticals Inc - expect to complete phase 1 study of edp-305 mid-year and later this year plan to initiate a phase 2 study of edp-305 in pbc

* Enanta -expect to complete phase 1 study of edp-305 mid-year and later this year plan to initiate a phase 2 study of edp-305 in pbc

* Enanta Pharmaceuticals Inc says also plan initiation of clinical development of our lead rsv compound, edp-938 in calendar 2017 Source text for Eikon: Further company coverage:

Our Standards:The Thomson Reuters Trust Principles.
0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below